Biosimilar Labeling In US Needs Greater Transparency, BIO And PhRMA Say

The US Food and Drug Administration's current approach to biosimilar labeling lacks transparency and requires changes to align with the agency's own Transparency Initiative, a joint citizen petition from two biopharmaceutical trade groups suggests1.